AP1903

Phase 1Small molecule

BBellicum Pharmaceuticals

AP1903 is one of 166 small molecule programs targeting Suicide. It is currently in Phase 1.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

SuicideActive, not recruiting

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

SuicidePhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

DATROWAY

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Active, not recruiting

Acute Lymphoblastic Leukemia

NCT01494103

Q3 2040

Phase 1Active, not recruiting

Lymphoma

NCT03696784

Clinical

Trials by Indication[1]

Breast Cancer1 trial

T-Cell Therapy for Advanced Breast Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02792114·186 enrolled

Solid Tumors1 trial

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02107963·15 enrolled

Prostate Cancer1 trial

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Completed·BBellicum Pharmaceuticals·Phase 1·NCT00868595·18 enrolled

Lymphoma1 trial

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03696784·19 enrolled

Lymphoid Malignancies1 trial

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03056339·49 enrolled

4 more indications

Suicide1 trial

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01875237·3 enrolled

Advanced Hematologic Malignancies1 trial

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

Withdrawn·BBellicum Pharmaceuticals·Phase 1·NCT02487459

T Cells1 trial

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

No longer available·UUNC Lineberger Comprehensive Cancer Center··NCT03594162

Acute Lymphoblastic Leukemia1 trial

Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene

Active, not recruiting·BBaylor College of Medicine·Phase 1·NCT01494103·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for AP1903. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AP1903 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AP1903. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bellicum Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBellicum Pharmaceuticals

AP1903

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2040

Trials by Indication[1]

Breast Cancer1 trial

Solid Tumors1 trial

Prostate Cancer1 trial

Lymphoma1 trial

Lymphoid Malignancies1 trial

Suicide1 trial

Advanced Hematologic Malignancies1 trial

T Cells1 trial

Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News